View Older Stories View More Recent Stories

May 16, 2019 07:00AM G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 13, 2019 07:00AM G1 Therapeutics to Present at UBS Global Healthcare Conference
May 13, 2019 07:00AM G1 Therapeutics to Present at UBS Global Healthcare Conference
May 9, 2019 04:01PM G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update
May 2, 2019 07:00AM G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019
May 2, 2019 07:00AM G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019
Apr 29, 2019 04:54PM G1 Therapeutics (GTHX) Reports Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
Apr 29, 2019 04:01PM G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
Apr 29, 2019 04:01PM G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
Apr 2, 2019 07:00AM G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Apr 2, 2019 07:00AM G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Mar 4, 2019 07:00AM G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference
Mar 4, 2019 07:00AM G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference
Feb 28, 2019 04:01PM G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
Feb 27, 2019 07:00AM G1 Therapeutics to Host Investor Day 2019 on March 6, 2019
Feb 27, 2019 07:00AM G1 Therapeutics to Host Investor Day 2019 on March 6, 2019
Feb 21, 2019 07:00AM G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019
Feb 21, 2019 07:00AM G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019
Dec 27, 2018 07:00AM G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
Dec 27, 2018 07:00AM G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
Dec 19, 2018 04:02PM G1 Therapeutics (GTHX) Reports Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line SCLC
Dec 19, 2018 04:01PM G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
Dec 19, 2018 04:01PM G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
Dec 4, 2018 06:56AM G1 Therapeutics (GTHX) Reports Prelim. Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy
Dec 4, 2018 06:55AM Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
Dec 4, 2018 06:55AM Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
Nov 26, 2018 04:03PM G1 Therapeutics (GTHX) Announces Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq in First-Line SCLC
Nov 26, 2018 04:01PM G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Smal
Nov 26, 2018 04:01PM G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Smal
Nov 9, 2018 07:40PM G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Nov 9, 2018 07:40PM G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Nov 7, 2018 04:01PM G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update
Nov 6, 2018 07:00AM G1 Therapeutics to Present at Investor Conferences in November 2018
Nov 6, 2018 07:00AM G1 Therapeutics to Present at Investor Conferences in November 2018
Oct 30, 2018 06:00AM G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
Oct 30, 2018 06:00AM G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
Oct 22, 2018 05:44AM G1 Therapeutics (GTHX) Highlights Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of SCLC
Oct 21, 2018 08:45AM G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
Oct 21, 2018 08:45AM G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
Oct 9, 2018 07:03AM G1 Therapeutics (GTHX) to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at ESMO
Oct 9, 2018 07:00AM G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
Oct 9, 2018 07:00AM G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
Sep 17, 2018 06:00AM G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018
Sep 17, 2018 06:00AM G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018
Sep 13, 2018 07:08AM G1 Therapeutics (GTHX) Names Garry Nicholson to Board
Sep 13, 2018 07:00AM G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors
Sep 13, 2018 07:00AM G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors
Aug 28, 2018 06:00AM G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
Aug 28, 2018 06:00AM G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
Aug 8, 2018 04:01PM G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
View More Recent Stories View Older Stories